SPHK1 and cancer: The modulation of S1P signaling is a promising avenue for cancer therapy, with SphK inhibitors and FTY720 (a functional S1PR antagonist) shown to inhibit cancer cell proliferation and tumor growth in both in vitro and in vivo models [8].